ResMed's NightOwl Sleep Apnea Test Drives $323M Trading Volume, Ranks 441st Despite Stock Decline

On April 3, 2025, ResMed (RMD) experienced a significant increase in trading volume, with a turnover of $323 million, marking a 132.19% rise from the previous day. This surge placed ResMed at the 441st position in the day's stock market rankings. However, despite the high trading volume, ResMed's stock price declined by 4.33%.

ResMed, a leading health technology company, has introduced NightOwl, a home sleep apnea test designed to simplify the diagnosis of obstructive sleep apnea (OSA). This FDA-cleared device allows individuals to complete a sleep apnea test from the comfort of their own home using a small fingertip sensor and a smartphone. The test captures up to 10 nights of sleep data, providing a comprehensive view of an individual's sleep patterns. The data is then sent to a cloud-based diagnostic platform for physician analysis, enabling quicker and more efficient diagnoses.

NightOwl's features include auto-scored results, seamless integration with ResMed's Somnoware, and full disposability, which reduces operational burdens for healthcare providers. The device pairs with ResMed's myAir app, offering step-by-step guidance throughout the testing process. NightOwl uses peripheral arterial tonometry technology, which has been clinically validated against polysomnography (PSG) for its diagnostic accuracy. This technology measures blood flow changes, oxygen saturation, and pulse rate changes to detect OSA.

ResMed's launch of NightOwl is a significant step forward in making OSA testing more convenient and accessible. The company aims to help people achieve their full potential through better sleep and breathing, with care delivered in their own home. NightOwl is now widely available across the United States, and individuals interested in the device should consult their healthcare provider for more information.